Evidence map›Paper›PMID 36471025›Full record

ArticlePharmaceutical research2023

Analytical Workflows to Unlock Predictive Power in Biotherapeutic Developability.

Markos Trikeriotis, Sergey Akbulatov, Umberto Esposito, Athanasios Anastasiou, Oksana I Leszczyszyn

Abstract read
In one paragraph

Article in Pharmaceutical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Markos TrikeriotisResearch and Development, Malvern Panalytical Limited, Grovewood Road, Malvern, WR14 1XZ, Worcestershire, UK. markos.trikeriotis@malvernpanalytical.com.ORCID http://orcid.org/0000-0002-9299-5177
Sergey AkbulatovResearch and Development, Malvern Panalytical Limited, Grovewood Road, Malvern, WR14 1XZ, Worcestershire, UK.
Umberto EspositoResearch and Development, Malvern Panalytical Limited, Grovewood Road, Malvern, WR14 1XZ, Worcestershire, UK.
Athanasios AnastasiouResearch and Development, Malvern Panalytical Limited, Grovewood Road, Malvern, WR14 1XZ, Worcestershire, UK.
Oksana I LeszczyszynResearch and Development, Malvern Panalytical Limited, Grovewood Road, Malvern, WR14 1XZ, Worcestershire, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeForming accurate data models that assist the design of developability assays is one area that requires a deep and practical understanding of the problem domain. We aim to incorporate expert knowledge into the model building process by creating new metrics from instrument data and by guiding the choice of input parameters and Machine Learning (ML) techniques.

methodsWe generated datasets from the biophysical characterisation of 5 monoclonal antibodies (mAbs). We explored combinations of techniques and parameters to uncover the ones that better describe specific molecular liabilities, such as conformational and colloidal instability. We also employed ML algorithms to predict metrics from the dataset.

resultsWe found that the combination of Differential Scanning Calorimetry (DSC) and Light Scattering thermal ramps enabled us to identify domain-specific aggregation in mAbs that would be otherwise overlooked by common developability workflows. We also found that the response to different salt concentrations provided information about colloidal stability in agreement with charge distribution models. Finally, we predicted DSC transition temperatures from the dataset, and used the order of importance of different metrics to increase the explainability of the model.

conclusionsThe new analytical workflows enabled a better description of molecular behaviour and uncovered links between structural properties and molecular liabilities. In the future this new understanding will be coupled with ML algorithms to unlock their predictive power during developability assessment.

Indexed as

Antibodies, MonoclonalCalorimetry, Differential ScanningWorkflowAntibodies, Monoclonalaggregationcolloidal stabilityconformational stabilitymachine learningmonoclonal antibody

Identifiers

PMID36471025
PMCPMC9944381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.